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ent. There were 69 paired sera from infants in group I and 63 6om 
group 11. The geometric mean titer (GMT) of antibody against 
polivirus was significantly higher in group I1 compared to group I. 
There was no difference in the GMT for prp and pertussis among 
the two groups; however, tetanus and diphtheria antibody levels were 
lower in group 11. The rate of seroprotection was comparable 
between the two groups for all vaccine antigens. The protective anti- 
body titers for poliovirus 1, 2 and 3 were 98.596, 100% and 98.5% 
respectively for group I, and 96.8%. 100% and 93.6% respectively for 
group 11. 
Conclusions: Sequential vaccination with IPV and OPV leads to 
high protective antibody levels. The clinical significance of decreased 
antibody titers of tetanus and diphtheria is not known. 
m1 Quorum-sensing blockers based on the 
Staphylococcus epidermidis agr pheromone 
M. Otto, R. SiiBmuth, C. Vuong, G. Jung, E Gotz. Universitdt 
Tiebingen, Mikrobielle Genetib, Tuebingen, Germany 
The agr quorum-sensing system in staphylococci controls the 
production of suriace proteins and exoproteins. In the pathogenic 
species Staphylococcus anreus, these proteins include many virulence 
factors. The extracellular signal of the quorum-sensing system is a 
modified peptide pheromone, whose sequence varies among the 
different staphylococcal strains. Previously we have shown that the 
modification in the S. epidermidis pheromone is a thiolactone struc- 
ture linking a central cysteine residue to the C-terminal carboxy 
group (Otto M, SiiRmuth R, Jung G, Gotz F. Structure of the 
pheromone peptide of the S. epidernridis agr system. FEBS Lett1998; 
424: 89-94). This structure is likely to be conserved in all staphylo- 
coccal agr pheromones. We demonstrate that a synthetic S. epider- 
midis pheromone is a competent inhibitor of the S. aureus agr system. 
Derivatives of the pheromone, in which the N-terminus or the cyclic 
bond structure was changed, were synthesized and their biological 
activity was determined. The presence of a correct N-terminus and 
a tholactone were prerequisites for an agr-activating effect in S. 
epidermidis, whereas inhibition of the S. anreus agr system was less 
dependent on the original structure. One derivative showed efficient 
repression of the S. aureus system, but had lost the ability to activate 
the S. epidermidis system. Our results show that effective quorum- 
sensing blockers that suppress the expression of virulence factors in 
S. aureus can be designed based on  the S. epidermidis pheromone. 
DNA as vaccine or therapeutic against cancer 
and viral infections 
K. Moelling, J. Pavlovic, J. Schultz, Th. Schuh, E. Obraschall, L. 
Heinzerling. Institute of Medical Virology of the University of Zurich, 
Zurich, Switzerland 
Plasrmd DNA encoding viral or tumor-associated antigens can 
induce protective immune responses against challenge with virus or 
tumor cells when the DNA is injected intramuscularly (Moelling K. 
J Mol Med 1997; 75: 2 4 2 4 ;  Moelling K. Cytokines Cell Mol Ther 
1997; 3: 127-36; Moelling K. Gene Ther 1998; 5: 573-4). We are 
developing a DNA vaccine against malignant melanoma with a 
tumor and a metastasis model in mice using a melanoma-associated 
antigen and a number of cytokine-encoding DNA plasmids such as 
IL-2, GM-CSF, IL-12, and the co-stimulator B 7.1. Depending on 
the type of cytokine, some tumor reduction was observed, while 
metastasis in the lung was strongly inhibited. Systemic expression of 
cytokines was monitored over time and was long-lasting. Nonspecific 
CpCs showed only transient efi>cts. The protective immune response 
is analyzed using various genetically altered mice such as perforin, 
interferon receptor (IFN-Ka), CD8+ cell and B-cell knockout mice. 
The mice were also immunized with viral DNA coding for influenza 
A hemagglutinin and nucleoprotein, HIV-1 gag-pol, NC, bunya viral 
antigens and CMV antigens. Combinations of viral antigen-encod- 
ing DNA with DNA encoding cytokines or peptides are under inves- 
tigation. 
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m1 Methenamin hippurate in chronic relapsing 
pyelonephritis (CRP) 
LSilan, V Krcmery Jr'. G. Kovac', L. Langsadll, S. Nyulassy', J. 
Breza'. 'Derers Hospital, Department of Internal Medicine, Department 
of Clinical Biorhemistry, Department o f  Microbioloa and Immunology, 
Department o f  Urology, 'Pospaduate Medical School, Bratislava, Slovak 
Republic 
In a group of 84 patients (12 men and 72 women, aged 15-60) with 
CRP, the organotoxicity, metabolic changes, adverse effects and 
antibacterial activity of M-H in long-term treatment is reported. The 
drug was administered for 6-27 months in a 0.5-2-g dose with ascor- 
bic acid. N o  organotoxicity or immunotoxicity was established. A 
slight decrease of hemoglobin and an increase in the acidity of urine 
were demonstrated. No serious adverse effects appeared. A rapid 
decrease in the bacterial count in Enterobacteriaceae, Proteus, 
Klebsiella, Serratia, Pseudomonas species and microorganisms causing 
sexually transmitted diseases (Mycoplasma, Ureaplasma, Gardenerella, 
etc.) could be demonstrated. Prophylaxis with M-H can reduce the 
rate of relapses in patients suffering from C R P  from 3-6 per year to 
nearly 0 per year. After termination of the therapy, 80-85% of 
patients were relieved of symptoms for prolonged periods, and there 
were no long-term effects after termination of therapy for 60%. 
Long-term M-H therapy does not cause resistance of bacteria or 
selection of resistant mutants of gastrointestinal flora. Methenamin 
hippurate seems to be effective in the prevention of chronic 
pyelonephritis relapses. 
Ip172] Evaluation of antiviral activity of new 
benzimidazole derivatives 
G. Gentilomi', L. Garuti', M. Robert?, S. Venturoli', E. 
Manaresil, N.I. Zerbini', M. Musiani'. 'Department of Clinical and 
Experimental Medicine, Microbiology Section, 'Department of 
Pharmaceutical Science, University of Bologna, Italy 
The versatility of benzimidazole and its potential to yield derivatives 
with a wide range of biological activity has made it a useful structure 
for further molecular exploration. It is well known that several benz- 
imidazoles 1-rubstituted are antiviral agents and good inhibitors of 
R N A  viruses. In our study we evaluated the antiviral activity of a 
series of newly synthesized benzimidazole-N-carbamates. Consider- 
ing the importance of the substituents at position 2 of this heterocy- 
cle, we have introduced different groups. The choice of the chains 
linked at the C-2 was made in view of their presence in other classes 
of antiviral compounds. An amide group appeared in L-737,129; an 
ester function was crucial for activity in some aryl pyrrolyl sulfone 
A b s t r a c t s  1 3 1  
derivatives; also, thc sulfonyl group led to important derivatives. 
Sonic 2-substituted-henzimidazole-N-carbdmates were synthesized 
aiid tested in vitro for antiviral activity. Two derivatives were active 
at non-cytotoxic concentrations. The results confirmed the inipor- 
tance of the suhstituent\ at the 2-position of benzimidazole and 
suggest that other suhstituents at the 2-position could lead to 
groups according to their erythromycin wsceptibility: 50 susceptiblc 
(EKY-S), and 27 resistant (EKY-R). The  percentages of PEN-resis- 
tant strains in each group were: 26% of EKY-S, aiid 66.7% of ERY- 
R. S. inifis was the species most frequently isolated (77.W1) and 
showed a high rate of PEN (43.%)and ERY (38.5%) resistancc. The 
MICif, and MIC~I,> (mg/niL) were as follows: 
compounds with useful antiviral activity 
In vitro activity of HMR 3647 against anaerobic 
bacteria 
C .  Privitera, E. Cknte, (1. Zanca, A. Zainbelli, A. Pagano, 
L T i i i i ~ ~ ~ r ~ I f y  of Milmi, brstitirt of Hyfiivic, Milaw, Italy 
Objectives: To determine the in vitro bacteriostatic and bacterici- 
dal activity of H M R  3647 in comparison with other rnacrolides and 
referciice aiitiiiiicrohid agents with good activity against anaerobic 
bacteria. 
Methods: The activity of H M K  3647 was assessed against 218 
recent clinicnl isolates fioiii human infections by the agar dilutioii 
method according to the NCCLS standards in comparison with 
azithroniycin, clarithroniycin, roxithroniycin, erythroniycin, cefox- 
itin, clindaniycin and metronidazole. The influence of pH (7.0-7.6) 
and of inoculum size (105 versus lo7 CFU/spot) was also assessed. 
The miiiinial bactericidal coiicentrations were assayed by broth 
microdilution oii 12 strain? of B. fiaxiLi.r and the time-killing curves 
determined by using a concentration equal to 2 Y MBC. 
Results: Overall, H M R  3647 was the most active agent tested 
among the macrolides, its activity being the highest against clostridia 
and equal to that of clarithroniycin for bacteroide\. The MlCjil and 
MICCX were respectively 0.5 and 4 mg/L for B. ja,@/is,  0.25 aiid 
X mg/L for Bactemidc.s species other than B. j q i l i s ,  0.06 and 
0.125 mg/L for C. pcfrii7pris,  0.125 and 4 mg/L for C. difficile, and 
0.1 25 and 16 mg/L for Clostridiirrii spp. The activity of H M K  was 
only slightly influenced ( M I C ~ I I  0.06-0.125 iiig/L) by lowering the 
pH to 7.0 and hy increasing the inoculum size to 107 CFU/spot. The 
time-killing curves showed complete killing of the ~noculuni by the 
8th hoiir. 
Conclusions: H M R  3647 exerted good activity against clinically 
relevant anaerobic bacteria and may he a useful agent for the treat- 
inent and prophylaxis of anaerobic infections. 
m1 In vitro activity of the new ketolide HMR 3647 
in comparison to other eight antibiotics 
against viridans group streptococci isolated 
from blood of neutropenic cancer patients 
F. Alcalde, M.A. Benitez, J. Carratah, E Gudiol, J. Linares, K. 
Martin. Departi~~errts cfMirrdio/o<y aiid Ic!frctious Diseases, Cirrtat 
.itdria dc Bellvige, Uvriversity of Barcelorra, Spairi 
Objectives: To determine the susceptibilities of viridans group 
streptococci (VCS) isolated from blood of neutroprnic cancer 
patient\ (NCPs) to the new ketolide H M K  3647 in coniparison to 
eight other antibiotics. 
Methods: Seventy-seven consecutive blood culture isolates of 
VGS froin NCI's, during 1988-97, were tested for anti- 
niicrohid susceptibilities by the iiiicrodilution method (NCCLS). 
The antibiotics studied were: penicillin (PEN), cefotaxinie (CTX), 
erythromycin (ERY), clindaiiiycin (CLl), vancomycin (VAN), chlo- 
raniphenicol (CHL). co-trinioxazole (SxT), ciprofloxacin (CIP), and 
H M R  3647 (HMK).  
Results: 40.3% of the isolates showed decreased \usceptihility to 
PEN (MIC range: 0.25-16). The strains were classified into two 
ERY PEN CTX CLI VAN CHL SxT CIP IlMR 
S MICx 0.06 0.06 0.12 0.5 4 0 5  2 50.03 mcQl 4 2 0.5 1 4 4 4 50.03 . 
0.5 4 2 4 OM 
MI& 4 4 2128 1 8 4 8 1- 
R MICm 2 1 1 
Conclusions: Our  study shows a high rate of penicilliri and 
erythromycin resistaiice anioiig VGS isolated froiii blood of NCl's. 
However, the new ketolide H M K  3647 was the iiiost active aiitiiiii- 
crohial tested, and it could be useful as a prophylactic agent to prevent 
VGS bactereiiiia in neutropcnic cancer pments. 
In vitro activity of HMR 3647 and six other 
antimicrobial agents against anaerobic bacteria 
G. Ackerniann, K. Schauinann, B. Pless, M. Clams, A.C.  Rodloff. 
bistitrrfe ofA4edicnl lbficrobiolo'yy and Epideiriiolqy I$ Zr!frctioits Di.teases, 
f i i i i imci ry  of Lfipztq, Gerrtiaciy 
Objectives: The 111 vitro activity o fa  new ketolide, HMK 3647, and 
of reference antibiotics was tested against 292 clinical isoldtes ofoblig- 
ately anaerobic bacteria employing the broth iiiicrmiilution tech- 
nique. M l C  distributions were recorded and graphically displayed. 
Methods: In the present study, we asswed  the antimicrobial activ- 
ity of H M K  3647, nietronidnzole, chnddmycin, imipeiicm, tetracy- 
cline, chloramphenicol and penicillin against the following 292 
strains: Bartcroides spp. (n= 197), Prevotella spp. (n= t I ) ,  Fiisobacrerirrrrr 
spp. ( i f =  17), Bilopliila icxdsivorfhia (n=29), Clostridiitnt spp. (n=29), 
and Pcprostreptocorcirs spp. (n=Y). MlCs were determined employing 
the broth microdilution technique and Wilken-Chalgren broth. 
Results: MIC:~,I and ICW, for H M K  3647 wcre (i~ig/L) 114 for 
Bacteroidr's j q i l i s ,  Bacteroida ova~its, Bucteroider thetaiotaornrcruir, 
Fiisubnrten'iiw~ spp. and Biiophita wadsworrltia, 2/2 for Bartwoides carem, 
1 /4 for Bacteroidcs vrr&us, 0.25/4 for Prcootella spp., and < =0.03/0.5 
for Closfridiiti?~ spp.. respectively H M R  3647 was more dctive than 
clindamycin, tetracycline, chlormiphenicol and penicillin against the 
anaerobes tested here. However, metrnniddzole and iinipeiieiii inhih- 
ited the same organisms at concentrations three and two dilution steps 
lower than H M K  3647, respectively 
Conclusion: These results indicate that H M K  3647 iiidy be 
useful clinically in the treatment of anaerobic infectioiis. 
/p176) Comparative in vitro activity of a novel 
ketolide antimicrobial agent, ABT773 (ABT), 
and the activity of HMR4004 (HMR), 
erythromycin (ERY). clarithromycin (CLA) and 
azithromycin (AZI) versus Streptococcus 
pneumoniae 
A.B. Brueggemann, E.M. Wiiigert, H.K. Huynh, PI<. IUiomberg, 
G.V. lloern, f l n i i w s i t y  of Ioti~u, Dept. of Pathology, Ioum Cirl~, USA 
Objectives: Evaluation of the antimicrobial activity of a new 
ketolide agent, ABT, versus a recent collection of S. pnrunioiiia~. 
Comparison of the activity of ABT and that of another ketolide, 
H M R ,  and the macrolides ERY, CLA and AZI. 
Methods: Unique isolates of S. pircuim~i~iiae (PI= 1001) were 
collected from 34 US medical centerr during thc winter month\ of 
1997-98. Broth microdilution susceptibility testing using 
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Mueller-Hinton broth plus 5% lysed horse blood was performed 
following NCCLS guidelines explicitly 
Results: ABT had the highest level of inhibitory activity among 
all agents compared in this study: 78.9% of organisms tested had an 
ABT MIC of 10.008 mg/L. ABT was consistently one doubling 
dilution more active than HMR. The MICso, MICuo and range 
(mg/mL) of each agent were as follows: ABT, <0.008, 0.03, 
<0.03-64; CLA, <0.03, 4, <0.03-64; and AZI, 0.12, 16, 
<0.03-64. S. pneumoniae contains two main mechanisms of 
macrolide resistance, ermAM, a ribosomal methylase which typically 
results in ERY MICs of 64 mg/L, and me&, an efflux pump which 
usually results in ERY MICs of 1-32 mg/L. This population 
contained 5.0% (n=80) and 13.9% (n=222) organisms suspected of 
being ermAM and mefE, respectively, based on their ERY MICs. In 
comparison, 4.1% (n=65) of organisms had an ABT MIC of 
0.015 mg/L and an ERY MIC of 1-32 mg/L. Similarly, 11.4% 
(n=182) oforganisms had an ABT MIC of0.015 mg/L and an ERY 
MIC of 64 tng/L. This may suggest a possible correlation between 
ERY resistance mechanisms and higher ABT MICs. 
Conclusions: ABT displayed the greatest antimicrobial activity of 
the ketolide and macrolide agents tested in this study and therefore 
looks to be a very promising new antimicrobial agent. 
<0.008-0.5; HMR, 0.015, 0.06, <0.004-2; ERY, 0.06, 8, 
Comparative in vitro activity of ABT-773, a 
novel antibacterial ketolide 
A.M. Nilius, M. Bui, L. Almer, D. Hensey, J. Beyer, Z. Ma, Y.S. 
Or, R.K. Flamm, Abbott Laboratories, Abbott Park, IL, USA 
Objectives: The in vitro activity of ABT-773, a novel ketolide 
derived from erythromycin A, was evaluated and compared with the 
activity of erythromycin, clarithromycin, and azithromycin. 
Methods: Antibacterial activity was determined by agar dilution 
against groups of aerobic, anaerobic and fastidious pathogens. 
Results: ABT-773 was more potent in vitro than the macrolides 
against Haernophilus influenzae, Moraxella catarrkalis, Legionella spp., 
Neisseriagonorrhoea and Listeria monocytogenes with MICXIS of 4 mg/L, 
0.12 mg/L, 1 mg/L, 0.25 ing/L and 0.03 nig/L, respectively It was 
also more potent against macrohde-susceptible strains of Streptococcus 
pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus 
epidermidis, Enterococcus spp., Helicobacterpylori and Mycobacterium avium 
complex with MICm of 0.03 mg/L, 0.03 mg/L, 0.03 mg/L, 
0.03 mg/L, 0.03 mg/L, 0.06 mg/L, and 64 mg/L, respectively ABT- 
773 was more potent against Corynebacterium spp.. Mycoplarma pneu- 
moniae, Chlamydia trachomatis, Borrelia burgdotjirii, and anaerobic 
species. Unlike the macrolides, ABT-773 had potent activity against 
erythromycin-resistant strains of streptococci and enterococci. But 
ABT-773 and the macrolides had little to no detectable activity 
against constitutive MLSv-resistant staphylococci, and macrolide- 
resistant H. pylori and Mycobacterinm avinm complex. 
Conclusions: ABT-773 possesses significant advantages in 
potency and antimicrobial profile compared to marketed macrolide 
antibiotics, suggesting that ABT-773 may be a therapeutically useful 
new antibacterial agent. 
[ PI78 1 Activity of the ketolide ABT-773 as measured 
by broth microdilution against macrolide- 
susceptible and macrolide-resistant 
Streptococcus spp. 
D. Shortridge, N. Ramer, A. Darwish, R.K. Flamm, Abbott 
Laboratories, Abbvft Park, IL, USA 
Objectives: The activity of a new ketolide, ABT-773, was compared 
to the activity of erythromycin, azithromycin and clarithromycin 
against 300 S. pneumoniae and 120 S. pyogenes clinical isolates that 
were susceptible to or resistant to macrolide antibiotics. 
Methods: Susceptibility testing was performed using the NCCLS 
standard reference method for streptococci. This method employs 
Mueller-Hinton broth with 3% lysed horse blood. Incubation was in 
ambient air at 37°C for 20-24 h. 
Results: The ketolide ABT-773 had 10-fold better activity than 
the macrolides against 99 macrolide-susceptible S. pneumoniae strains. 
The M I C ~ I I  for ABT-773 was 0.002 mg/L. ABT-773 was far supe- 
rior in activity than the macrolides against 201 macrolide-resistant 
isolates of S. pneumoniae which had either macrolide efflux (MEF) or 
ribosome methylase (ERM) resistance mechanisms. The MICw for 
ABT-773 against 101 MEF strains was 0.12 mg/L. Against 100 ERM 
strains, the ABT-773 MICYU was 0.015 mg/L. The ketolide was much 
more active than the macrolides against susceptible S. pyogenes (MICW 
<=0.002, n=30). ABT-773 had improved activity over the 
macrolides against macrolide-resistant S. pyogenes with either MEF or 
ERM. The ABT-773 MICW for 60 MEF strains was 0.12 mg/L. 
Against 30 ERM strains of S. pyogenes, the ABT-773 MICcw was 
0.5 mg/L. 
Conclusions: The new ketolide ABT-773 has superior activity 
compared to macrolides against both macrolide-susceptible and 
macrolide-resistant streptococci, regardless of resistance mechanism. 
v] Efficacy of ABT-773 against acute systemic 
bacterial infections in mice caused by resistant 
Streptococcus pneumoniae 
PA. Ewing, M.J. Mitten, J.A. Meulbroek, D. Shortridge, J.D 
Alder, Abbott Laboratories, Abbott Park, IL, USA 
Objectives: To evaluate the eficacy of ABT-773, a new ketolide, 
against resistant Streptococcus pneumoniae in murine models of acute 
systemic infection. 
Methods: CF-1 female mice were inoculated intraperitoneally 
with Streptococcus pneumoniae 6303 (MLS-S, Pen S), Streptococcus pneu- 
moniae 6502 (MLS-S, Pen R),  Streptococcus pneumoniae 5649 (mefE. 
Pen I ) ,  Streptococr~rLlspneumonz~e 5654 (me&, Pen R), Streptococcus pneu- 
inoniae 6396 (ermAM, Pen S), Streptococcus pneumoniae 5669 (ernuPM, 
Pen I), Streptococcus pneumoniae 5979 (ermAM, Pen R), prepared from 
broth cultures adjusted to approximately 100XLDso. A 100% mortal- 
ity rate was produced in all untreated inoculated mice. ABT-773 (by 
peroral gavage) and penicillin (by subcutaneous injection) were 
adrmnistered at 1 and 5 h post-inoculation. Mice were monitored 
daily for mortality for 7 days. EDso values were calculated from 
cumulative mortality by logarithmic-probit analysis of a plotted curve 
of survival versus dosage. There were 10 mice per dosage group. 
Results: The ABT-773/penicillin EDSO values (mg/kg per day) 
were: 4.6/< 1 2 5  against strain 6303; 12.4/167.4 against strain 6502; 
50.1/20.0 against strain 5649; 52.W109.0 against strain 5654; 
50.1122.2 against strain 6396; 14.7124.1 against strain 5669; and 
10.3/800 against strain 5979. 
Conclusions: ABT-773 was highly effective in treating acute 
systemic infections caused by resistant Streptococcus pneumoniae. 
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Table A I Curedflmprov. N(%) 
High dose N=151 1 134 (88.7%) 
Low dose N=120 I lOO(83.3%) 
Ip1801 In vitro activity of linezolid with or without 
aminoglycosides against vancomycin-resistant 
enterococci 
Failed N(%j I Indeterm. N(%) 
7 (4.6%) I 10 (6.6%) 
8 (6.7%) I 12(1O%j 
K.E. Piper, M.S. Rouse, R. Patel, W.R. Wilson, J.M. Steckelbcrg. 
'Mayo chic, Rorhesfer, h'N, USA 
The in vitro activity of the new oxazolidinone linezolid (LD) with 
or without aiiiinoglycosides against vancomycin-resistant enterococci 
(VRE) was studied. Vanconiycin resistance genotype was deterimned 
by PCR amplification with primers specific for vanA, vanB, vanC1 
and vanC2/3. VRE MlCs were determined in 2 mL of cation- 
suppleniented Mueller-Hinton broth (CAMHB) with an initial 
inoculnni of 10' CFU/mL, as described by NCCLS documei~t M7- 
A4. MBCs were determined by subculture of the MIC tests accord- 
ing to NCCLS document M2h-T. The MICg,, of LD against 37 VRE 
war 4 mg/L (range 0 .54  nig/L) and all MBCs were 8 mg/L. Time- 
kill studies with one isolate of each van genotype were performed in 
CAMHU. The results are summarized below as the bacterial count 
after 24 h minus the initial inoculum at 16 mg/L of LD plus 5 mg/L 
gentamicin (GM) or 20 mg/L streptomycin (SM). 
I LD I GM I SM I LD16 ILD16+ILD16+1 
All isolates teqted were inhibited by < =4  mg/L of LD. No Tyner- 
gistic or antagonistic bactericidal interactions were detected with 1, 
2, 4, 8 or 16 mg/L of L1> plus 5 mg/L GM or 20 mg/L SM. Further 
studies of the activiw of LD are warranted. 
Ip1811 Efficacy of linezolid in skin and soft tissue 
infections 
Conclusions: Linezolid is an effective agent in the treatment of 
skin and soft tissue infections. 
[p1821 Ziracin Gram-positive survey in 22 countries 
R.S. Hare, EJ. Sabatelli, the Ziracin Susceptibility Testing Group. 
SiherinpPlonRh Research Imfi tufe ,  Kenilumrth, '\y> CISA 
Objectives: To ascertain the activity of a new everninoniicin antibi- 
otic, Ziracin (Z, SCH 27899), against a large number of recent 
Gram-positive clinical isolates in Europe. 
Methods: A multinational survey was organized to assess the 
antimicrobial activity of Z and other selected antibiotics against more 
than 4000 recent Gram-positive clinical isolates from Europe and 
South Africa. These strains were collected and tested in 22 centers 
(200 from each) in  22 different countries. Included were niost central 
European and Scandinavian countries and also many centers in east- 
ern Europe and one in South Africa. Using the Etest method for 
determining MICs (AB Biodisk), four groups of recent clinical 
isolates were tested: (1) 1003 strains of niethicillin-resistant staphylo- 
cocci; (2) 1097 strains of enterococci; (3) 1041 strains of Sfrrptoiorius 
pneumoniae; and (4) 1047 strains of other 'clinically significant' strep- 
tococci. 
Results: MICws for Z against the four groups were 1.0 (range 
0.016-6 mg/L), 0.75 (range 0.016-1.5 mg/L), 0 .064  (range 
0.016-1.0 mg/L) arid 0.25 mg/L (range 0.016-3.0 mg/L), recpec- 
tively Ofthe total group ofstrains, 99.9% were susceptible to Z, MIC 
< =2 mg/L (current proposed cut-off). 
Conclusions: Z is an antibiotic with an excellent spectrum of 
activity against all Gram-positive strains tested, including not only 
oxacillin (93.4%)- and erythromycin (75.0'%1)-resistant staphylococci, 
but also gentamicin (23.2%)-, vancomycin (1.9%- and quino- 
pristin/dalfopristin (77,7%)-resistant enterococci, as well as penicillin 
G (4.4%)- and erythromycin (20.1%)-resistant streptococci. 
Ip1831 Safety and efficacy study of ziracin (SCH 
27899) versus ceftriaxone in the treatment of 
acute bacterial pneumonia due to 
Sfreptococcus pneumoniae 
G. Martinez, J.M. Hill, T.Soler, G. Mukwaya, J. Gupte, A. 
LeBeaut. Hospital General SunJuan De Dim, Giratemala; C ~ i i t r ~ i  
Mediio Nacional, Mexico; ZNERYC?; Chile; Scherin*q-P/oqh Kcscarch 
Institute, Keniltvorrh, NJ USA 
Introduction: Ziracin is a novel everninoinicin antibiotic with 
broad-spectrum in vitro and in vivo activity against Gram-positive 
bacteria (including penicillin-sensitive and penicillin-resi~taiit S. 
pneumoniae). 
Objectives: A multicenter, randomized, evaluator-blindstudy 
compared the safety and efficacy of once-daily Ziracin (1 or 3 mg/kg 
per day) with once-daily ceftriaxone (2 g/day) IV for 3 days followed 
by oral amoyicillin ( I  g t.i.d.) for 7 days. 
Methods: Thirteen centers from Latin America recruited a total 
of 60 patients; 21 received Ziracin 1 mg, 20 received Ziracin 3 nig 
and 19 received ceftriaxone. Primary efficacy (modified intent to 
treat) was evaluated on day 4 at the end of IV study drug. 
Results: Clinical response (cure/iniproved) was achieved in 14/19 
(73%) of Ziracin (1 mg), 19/20 (95%) of Ziracin (3 mg) and 19/19 
(100%) of ceftriaxone patients. Microbiological eradication (actual or 
presumed) was achieved in 16/19 (84%) of Ziracin (1 mg), 19/20 
(95%) of Ziracin (3 ing) and 19/19 (100%) of ceftriaxone patients. 
The most conimon adverse events with Ziracin (1 and 3 ing) were 
injection site pain (4/41), elevated hepatic enzymes (4/41) and 
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phlebitis (2/41). For ceftriaxone, common adverse events were pain 
(3/19), respiratory disorders (2/19) and depression (1/19). 
Conclusions: Ziracin was as potent as ceftriaxone in treating 
acute bacterial pneumonia due to S. pneumoniae. A larger clinical 
study is warranted to confirm these results. 
Ip1841 In vitro antibacterial activity of everninomicin 
(SCH 27899) against Gram-positive clinical 
isolates 
PA. Siaperas, G.L. Petrikkos, A.E. Mandaraka, E. Xirouchaki, H. 
Giamarellou. Zst Departmenf of Propaedeutic Medicine, Infectious 
Diseases Laboratory, Athens Medical School, Athens, Greece 
Objectives: To check the in vitro activity of everninomicin against 
Gram-positive bacteria. 
Methods: The indiscriminate use of antibiotics has led to the 
appearance of Gram-positive resistant strains, which play a critical 
role in the treatment of a patient. Everninomicin (SCH 27899) seems 
to be an important agent against these organisms. The in vitro activ- 
ity of everninomicin (SCH 27899), a new oligosaccharide, was stud- 
ied in 195 clinical isolates-30 methicillin-resistant Staphylococcus 
aureus (MRSA), 20 methicillin-resistant Staphylococcus epidermidis 
(MRSE), 50 Enterococcrrs spp. (Ent. spp.), 45 Streptococcus pneumoniae 
(Strept. Pn), and 50 Streptococcus spp. (Strept. spp.)-in comparison 
with those of vancomycin (VAN), quinopristin-dalfopristin (RP 
59500, Rp), ceftriaxone (CTX), penicillin G (P), ciprofloxacin 
(CIP). erythromycin (ERY), chloramphenicol (CHL), and ampicillin 
(AMP). MICs were determined by using the Etest susceptibility 
methodology. 
Resilts : The MICJo Ad MiCw values ofEverninomicin respectively are : 
0,064 - 0,094 W S A ]  
0,064-019 W S E ]  
0,094 - 0,125 [Enterowcci spp.] 
0,047 - 0,125 [Strept spp.] 
<0,016 - 0,094 [Strept. pn.] 
Conclusions: The results above clearly indicate that SCH 27899 
has excellent in vitro activity against Gram-positive bacteria, and is a 
promising antimicrobial agent which needs further investigation. 
Ip1851 Susceptibility to everninomycin in Bulgarian 
strains of methicillin-resistant staphylococci 
and other problematic Gram-positive cocci 
E. Keuleyan. Medical University, Sqfia, Bulpria 
Objectives: To study in vitro susceptibility to everninomycin among 
methicillin-resistant Staphylococcus (MRSAIMRSE), high-level 
aminoglycoside-resistant (HLAR) and other Enterocoaw, penicillin- 
resistant (Pen-R1) and other Streptococcus pneumoniae and O-hemolytic 
Streptococcus. 
Methods: Determination of resistance to methicillin in staphylo- 
cocci, to high-level aminoglycosides in enterococci, and to penicillin 
in Streptococcus pneumoniae was done according to NCCLS guidelines. 
In vitro susceptibility testing of 50 strains by genus/species to everni- 
nomycin was by Etest (AB Biodisk) performed following the instruc- 
tions of the manufacturer. The media used were: Mueller-Hinton 
agar (National Centre for Infectious and Parasitic Diseases) (MHA), 
MHA=5% sheep blood and tryptic soy broth (Difco). For quality 
control, ATCC strains 22 213, 22 212 and 49619 were used. The 
values of MICso and M I C ~ O  were calculated by a graphical method. 
Results: The obtained MICs (mg/L) are presented in the follow- 
ing table: 
Conclusions: Everninomycin has shown exellent in vitro activ- 
ity against MRSA/MRSE, HLAR Enterococcus, Pen-R Streptococcus 
pneumoniae and other clinically significant Enterococci, Streptococcus 
pneumoniae and &streptococci. 
Ip1861 Value of albendazol in the treatment of hydatid 
disease of the lung 
G. Kondov, I .  Kondova, Z. Spirovski, R. Colanceski. Medical 
Faculty Skopje, Clinicfor nioracic Surgery, Skopje, Macedonia 
Albendazol is a helmiotherapeutic that attacks the destructive para- 
site that causes hydatid disease, invading the cyst, and destroying 
daughter cysts in the parent hydatid cyst. We conducted a critical 
analysis of 731 records ofpatients treated surgically for hydatid disease 
of the lung, some of whom also had hydatid disease of the liver. In 
the group of 491 patients who were were not given albendazol in 
prophylaxis, recidivation of the disease was detected in five patients. 
In the group of 240 given albendazol in prophylaxis, recidivation was 
detected in three patients. 
From the analysis we can see that relapse of the hydatid disease was 
detected in patients presenting complications before the first surgical 
intervention, such as perforation of the cyst into the bronchial tree 
or pleural cavity with dissemination of the daughter cysts, or inade- 
quate initial surgical therapy. 
Because of the toxicity of albendazol, especially to liver and blood 
cells, it is only indicated in patients with a complicated hydatid cyst 
before surgery. Adequate surgical treatment of the hydatid disease of 
the lung is the basic condition for prevention of recidivation of 
hydatid disease of the lung. 
Ip1871 In vitro activity of cefditoren pivoxil against 
Streptococcus pneumoniae 
A. Marton, C.S. Slrvlri. St LAszl6 Hospital, Budapesr, Hungary 
Cefditoren pivoxil is a new broad-spectrum oral cephalosporin, with 
strong in vitro activity against penicillin-resistant S. pneumoniae. In 
this study, MICs of cefditoren pivoxil were determined for 108 S. 
pneumoniae strains, susceptible, intermediately resistant and fully resis- 
tant to penicillin. While MIC5o and MICso were 8 and 16 mg/L for 
penicillin, they were only 0.5 and 1 mg/L for cefditoren pivoxil in 
the group of strains resistant to penicillin. The MICso and MI& of 
cefditoren pivoxil were 4 and 16 times lower in the group of S. pneu- 
m o n k  intermediately and fully resistant to penicJlin than for peni- 
cillin. Some isolates, mainly from the upper respiratory tract of 
children, showed extremely high MIC values to penicillin (as high as 
16 mg/L). However, the highest MIC of cefditoren pivoxil was 
2 mg/L (two strains). O n  the basis of its good in viuo activity, cefdi- 
toren pivoxil may be a potent drug in infections caused by penicillin- 
and multidrug-resistant S. pneumoniae. 
MICso and MIC9o of penicillin and cefditoren pivoxil (mg/L) 
S+ I' R' R a n ~ e  
Penicillin ( ~ 2 4 )  (n=23) (n*l) 
MICX) <=0.03 0.5 8.0 
Mlcaa <=0.03 1 .o 
Cefdiioren pivoxil 
MICs <=0.015 0.12 0.5 
M l c a a  0.03 0.25 1.0 =43.015-2.0 
+ susceptible. intermediately resistant and fully resicrtant 
16.0 <=O.W;r=32.0 
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lp1881 Adaptation of capillary electrophoresis for 
Tazocin analysis 
G. Pajchel, S. Tyski. Aritibiotics and Microbiolo‘qy Drpartmewt, Dnq 
Iristitirrc, Wirwr/, Poland 
Capillary electrophoresis (CE) is a relatively new but very promising 
analytic technique, which became conimon and popular in drug 
analysis for qualitative and quantitative determinations. The aim of 
this study was to adapt C E  for the determination of the drug Tazocin 
for intravenous infusions. Tazocin consists of piperacillin-urei- 
dopenicillin and fi-lactaiiiase inhibitor-tazobactaiii in the ratio 8: 1. 
Routinely, for simultaneous determination of piperacillin and 
tazohactdm, only the HPLC method is applied. CE  analyses were 
carried out at 2 5 T  on the Quanta 4000E System (Accu-Sep fused 
silica capillxy), qu ipped  with a 30-kV power supply and UV detec- 
tor (assay a t  214 tun) and able to perform hydrodynamic and voltage 
injection. Phosphate-borate buffer supplenmented with different S1X 
content (7-14 g/L) was applied. The separation was performed in 
the pH range 6-9 and at a voltage of  18 kV The influences of SDS 
concentrations and buf‘fer p H  on the migration of piperacillin and 
tazobactam were investigated. 
The migrcition time of piperacillin and tazobactani was longer 
when lower values of pH and higher SDS concentrations were 
applied. The  good reproducibility of the inigration time of both 
substances was achieved using CE buffer (pH 8.7) containing SDS 
7 g/L. I n  such conditions, excellent peak separation with migration 
time 6.3 Iniii for piprracillin and 7.6 min for tazobactam was 
observed. The  linearity was established for: piperacillin 0.64- 
24.0 mg/mL (r=0.9993), tazobactam 0.08-3 nig/inL (r=0.9999) and 
Tazocin 0.72-27.0 nig/niL. The detection liinit for both compounds 
was 0.01 mg/mL. The  statistical analysis of the obtaiiied results was 
confirmed by highly accurate methods (11SD= 1.99 for pipcracillm 
and RSD=2.15 for tazobactain). 
Ip1891 Antipneumococcal activity of MEN 10700, a 
new penem, compared to other compounds, 
by MIC and time-kill 
G. Pankuch, 11. Hoellnian, M .  Jacobq, P Appelbaum. Hershry 
Mcdirill Coirer, Hcvdrry, PA, and Case Wsterrr Rcscrw Utiivrrsily, 
Clri&rzd, O H ,  USA 
Objectives: To test the antipneumococcal activity of M E N  10700, 
a new penem, coinpared to those of amoxycillintclavulanate, cefo- 
taxinic, cefepime, meropeneni, ciprofloxacin, clarithroinycin and 
vanconiycin 
Methods: Against 57 penicillin-susceptible (S), 84 intermediate 
(I) and 81 penicillin-resistant (R) pneumococci, agar dilution MlCs 
were performed. Microbroth MICE and time-kills were done for four 
each ofpenicillin S, 1 and R pneuinococci. Time-kills were analyzed 
a t  0, 3, 6, 12 and 24 h. 
Results: Agar dilution MlC~ms (ing/L) of  MEN 10700 against 
penicillin-susceptible, intermediate and penicillin-resistant pneuino- 
cocci were 0.06, 1 .O and 2.0, compared to 0.06, 0.5 and 2.0 (amoxy- 
cillintcl~vulanate), 0.06, 0.5 and 4.0 (cefotaxime), 0.125, 0.5 and 
2.0 (cefepime), 0.03, 0.5 and 1.0 (meropenein), 2.0 (ciprofloxacin), 
0.125, 64.0 and 64.0 (clarithroinycin). and 0.5 (vancomycin). Time- 
kill assays with 12 penicillin-susceptible and penicillin-resistant strains 
showed that MEN 10700, at 4XMIC, was bactericidal (99.9% 
killing) for all 12 strains tested, with 99% killing of all strains after 
both 12 h and 24 h at 2XMIC. Kill kinetics of other B-lactains were 
similar to those of MEN 10700, relative to their MICs. Cipro- 
floxacin, at 4 x M I C ,  was hacteriridal against ail strains afier 24 h .  
Against tho cight clarithroniycin-susceptible strainq, clarithroinycin 
exhibited slow kill kinetics, with 99.9% killing of 6 / 8  strain$ after 
24 h at 4XMIC. Vancornycin was bactericidal agaitnt 11/12 strains 
at 2 X MIC after 24 h. 
Conclusions: M E N  10700, a new broad-spectrum penem, has 
excellent antipneumococcal activity by MIC and tnnc-kill against S, 
I and R strains. 
Activity of vancomycin and LV-333328 against 
intra- and extracellular enterococci resistant to 
vancomycin 
J. Swantes‘, U. Al-Nawas’, PM. Shah’. ‘Ihriimsiry Hiispifd, 
I~~fiktiolo~qie, Frankfurt, zCJniveriity Hospital, O r a l  and A4axill$kiol 
S i r i p y ,  Abfairzr, Germany 
Objectives: To assess the influence of thc different pharmocokiiirtic 
parameters of vanconiycin (VAN) and LY 333328 (LY) o n  intracel- 
lular activity against ~nferoocrrrc faec in tr~  and Errtevocociff~ j z e c d i s  resis- 
tant to VAN. 
Methods: After preincubation with 0.1, 1 and lo-fold MIC, the 
drug was washed out, and bacteria were phagocytowd by PMNa, and 
incubated for 4 h in drug-free medium. Results of viable intracellu- 
lar bacteria were compared to those of non-ingested enterococci. 
Two quality control strains (MICs for VAN 4 mg/L), two clinical 
isolates and two quality control strains of E. j k d i c  and E.  fnecirrm, 
both resistant to VAN (MIC 64-256 ing/L), were tested. 
Results: MICs of LY were 0.5-2 mg/L for 311 teated strains, 
regardless of their susceptibility to VAN. A reduction of extracellu- 
lar enterococci by VAN was found at concentrations of 1 and 10 MIC 
(64 and 640 ing/L), which are far above the clinically achievable 
concentrations. Against extracellular E.Jaeciitm, LY a t  1 MIC showed 
weak activity, killing 20% of extracellular bacteria after 4 h. At 10 
MIC, 99% of the iiioculuni was killed after 4 h. After preincubation 
and removal of the drug, no effect is seen for VAN against nitracel- 
lular enterococci. However, LY at 10 MIC (5-20 mg/L) had a bacte- 
rioqtatic effect with a reduction of 20-30’%1 of the inoculuin after 4 h. 
Conclusions: LY is more active at clinically achievable coiice~i- 
trations against extracellular E. Jaecicim and E. .firmtic than VAN. 
Against intracellular enterococci, LY is active even after removal of 
the extracellular drug 
I PI91 I PK and safety of multiple intravenous doses of 
~ ~ 3 3 3 3 2 8  
H.R. Thomasson, 11. Phillips, F3.P Smith, J.Y. Chien, Lill)~ 
Laboratory j k u  Cliriical Research, Indi~wapolis, Ily USA 
Objectives: To explore the safety and pharmacokinetics of 
LY333328 following inultiple doses in 1 0  healthy inen. 
Methods: Doses of 1.5 nig/kg were administered IV over 30 min 
once a day for 2, 3, 5 and 7 consecutive days to at least two subjects 
for each dosage regimen. I’lasina drug conceiitrmon cample\ were 
collected before the first infusion and daily for up to 500 h after the 
last infusion in the series. 
Results: Three of 10 subjectF experienced moderately cevere 
antecubital vein phlebitiv and four of 10 had mild phlebitis following 
at least two daily doses of LY333328. Asyinptomatic serum hepatic 
enzyme elevationc occurred in seven of 10 subjects; only two values 
reached two-fold above the upper limit of normal (ULN) but were 
three-fold ULN. All but one instance returned to normal within the 
obwrvation period. LY333328 mean m.ixinium plasma concentra- 
tion in nine subjects after the first I .5 mg/kg dose was 20 mg/L (37X 
CV). LY333328 ~naxiniu~n plasma conccntrationr did not appear to 
increase with multiple dosing. The averdgc minimum pla\iiia concc‘ii- 
136 C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  Vo lume 5 S u p p l e m e n t  3 
trations increased greater than two-fold with multiple dosing, due to 
the long terminal half-life (mean value was 277 h). The clearance and 
volume of distribution ( KS) of LY333328 after multiple dosing were 
0.0682 mL/min per kg and 0.760 L/kg, respectively However, 
modest between-subject variability was observed in the pharmacoki- 
netics of LY333328. 
Conclusions: LY333328 appears to be well tolerated and has 
apparent linear 
pharmacokinetics consistent with the results of single-dose stud- 
ies; the small study size calls for caution in interpretation of these 
conclusions. 
w1 Povidone-iodine liposome complex-a novel 
anti-infective for topical treatment 
K. Reimer', B. Brogrnann', H. Schreie?, I? WutzIer', G. Erdos4, 
S. Miillerl, €? Burkhard', A. Lanzendorfer', H.  Hoekstra', W 
Fleischer'. 'Mundipharma GmbH, Limbux, Germany; 'Advanced 
Therapies, Inc., Novato, USA; 'lnstitutfir Antivirale Chemotherapie, 
Efurt, Germany; 41nterdiscip/inary Centerfor Biotechnology Research, 
University of Florida, Gainerville, USA; 5Burns Research Institute, 
Bevenvijk, The Netherlands 
Objectives: Liposomal drug products are known to be more effec- 
tive and less toxic than the conventional drug formulations. 
Liposomes interact specifically with biological membranes. The 
pharmaceutical development of a combination of the anti-infective 
agent povidone-iodine (PVP-I) and liposomes can unite the excep- 
tional microbicidal activity of iodine with the excellent tolerability 
and drug delivery properties of liposomes. 
Methods: The PVP-I liposome complex was prepared as a liquid 
dlspersion and as a semi-solid hydrogel with different iodine concen- 
trations. 
Results: Electron-microscopic evaluations have indicated that the 
PVP-I liposomes attach directly to microorganisms, thus possibly 
facilitating the antimicrobial attack. In vitro studies on  the bacterici- 
dal activity (against Staphylococcus aureur) in comparison with the 
conventional PVP-I- formulations have demonstrated the higher effi- 
cacy of the liposome complex. In vitro cytotoxicity tests with differ- 
ent cell cultures have shown a cignificantly higher tolerability for 
iodine as the liposomal forinulation compared with the aqueous 
preparation. One aim of the developmental project is a well-toler- 
ated liposomal PVP-I- hydrogel for improved local anti-infective 
wound treatment. An animal study on the efficacy and tolerability of 
a liposomal hydrogel formulation with 3% PVP-I content in deep 
dermal burn wounds has indicated an outstanding quality of wound 
healing. A clinical study with the liposomal PVP-I hydrogel for anti- 
septic wound treatment is running. 
Conclusions: With the two formulations of a dispersion and a 
hydrogel of the PVP- I liposome complex, innovative topical anti- 
infectives in a modern drug delivery system for a number of possible 
indications are presented. 
vl Virucidal and chlamydicidal activities of 
povidone-iodine (PVP-I) liposomes 
P. Wutzler', A. Sauerbrei', R. Klocking', E. Straube', M. 
Schacke', R. Thust', W. Fleische?, K. Reimer'. 'Institutfur 
Antivirale Chemotherupie, Efurf ,  Zlnstirrrtfiir Medicd Mikrobiofoyie der 
Universitiit fena, fena, German)?, .?Mundipharma GmbH, Limbux, 
Germany 
Objectives: To investigate the inactivating properties of the new 
PVP-I liposomal preparations, containing 2.5% and 5.0% VP-iodine, 
against viruses and Chlamydia trachomatis strains. 
Methods: Human adenoviruc type 8 (AV 8). herpes simplex virus 
type 1 (HSV-I), coxsackievirus type A9 and C. trachomatis serotypes 
D and E were exposed to varying concentrations of the PVP-I lipo- 
somes for 0.25-15 rnin. The remaining infectious virus titers were 
determined by the TCID5o values and the residual chlamydia titers 
were measured by detecting inclusion bodies. PVP-I-induced cyto- 
toxicity against different cell lines was determined by an XTT-based 
tetrazolium reduction assay. 
Results: HSV-1 was inactivated by 4.5 loglo after exposure to the 
1 :40 diluted PVP-I liposomes for 0.5 min. Following 5 min of expo- 
sure to 1.5 diluted PVP-I liposomes, AV 8 was inactivated by 
4.9 loglrr. With 1.2 diluted PVP-I preparations, a reduction in 
coxsackievirus A9 titer of approximately 2 loglo was obtained. C. 
trachomatis strains were killed by 1 :40 diluted PVP-I-liposomes within 
0.25 min. 
Conclusions: In vitro, the new PVP-I liposomal preparations 
showed remarkable virucidal and chlamydicidal activity. 
UTI treatment using liposomal amikacin 
(MiKasome) 
J. Krieger, S. Childs, 1. Kliniberg, 1. Nicolle, K. Sandhaus, 
University .f Washington, Uroloz>< Seattle, WA, U S A  
Introduction: MiKasonie, a small unilamellar liposome-encapsu- 
lated amikacin, is designed to reduce aminoglycoside renal toxicity 
and ototoxicity and has a circulating half-life ofapproximately 1 week 
following intravenous infusion in humans. 
Objectives: To evaluate the safety and preliminary efficacy of four 
MiKasome dosage regimens for treating adults with complicated 
UTI. 
Methods: Four groups of patients are to receive MiKasome using 
an open-label, sequential design. Preliminary results are available for 
the first two groups: patients received either seven daily infusions of 
MiKasome at 10 mg/kg (group I, n=13 evaluable) or a single 
40 mg/kg infusion (group 11, n=22 evaluable). Bacteriologic and 
clinical cure were determined at 14 and 36 days from the start ofther- 
apy. Two fixed, single-dose groups, at 2 and 3 g, are still enrolling. 
Results: In group I, bacteriologic cure rates were 62% and 77%. 
and in group I1 they were 82% and 92%. The clinical cure rates were 
92% and 86% in group I, and 92% and 86% in group 11 (days 14 and 
36, respectively, in each pair). Among all patients with a bacterio- 
logic response at day 14, there was one recurrence at day 36 (1 of 
26). No clinically significant safety issues have been seen. 
Conclusions: MiKasome appears to be safe and effective in treat- 
ing patients with complicated UTI. A single infusion of 40 mg/kg 
appears to be as effective as seven daily infusions of 10 mg/kg. 
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m1 Enhancement of antibiotic activity by 
phospholipid 
K. Krogelt, PS. Cohen. Dcprfrnent .f Gastrointestinal Ipfictiows, 
Statci?s Scruin h t i r i r t ,  Coperihapi, Detrrnork; Departnieirt .f 
Biorhcniistry, M i c r o ~ i i o l q y  a n d  hlolrrnlar Gcnctiis, C.Tiziivrsity qf Rhode 
Island, Kingstun, RI, CJS.4 
Objectives: To sencitize Gram-positive and Gram-negative bacteria 
to antibiotics. 
Methods: Grow antibiotic-resistant bacteria in the presence of 
phospholipids and 
determine whether they become sensitive to antibiotics. 
Results: Pseudoniorias aeriqinosa became far more sensitive to the 
action 
of ampicillin when grown in the presence of phospholipids. In the 
absence of nionopalniitoyl-phosphatidic acid (MPPA), the MIC and 
MBC of ampicillin against I? aerufinosu PA01 were 2 mg/L and 
4 mg/L, respectively. In contrast, in the presence ofMPPA, the MIC 
and MBC were 20 mg/L and 40 mg/L, respectively. MPPA was 
shown to enhance anipicillin activity by binding both calcium and 
ii~agnesiuni, suggesting that the mechanism of enhancement is simi- 
lar to that previously reported for calciuni and magnesium chelators. 
Since iiionop~liiiitoylphosphatidyl choline (MPPC) would not be 
expected to bind calcium and magnesium, it was not curprising to 
find that MPPC did not enhance ampicillin activity againct P a e r q -  
nosa PA01 . Surprisingly, MPPA itself slowed the growth of several 
strains of I? aerqjnosn recently isolated from cystic fibrosis patients and 
enhanced the activity of piperacillin and ceftazidime against these 
strains. MPPA and MI'PC were shown to kill both methicillin-recic- 
rant StaphylCiroc,-1rs atireiis and vancomycin-resistant enterococci. 
Conclusions: MPPA and MPPC may be useful as antimicrobials 
or as enhancers of antibiotic activity. Since MPPC is inactive against 
I? acriqirrosa, it is likely that the mechanism of action of phospholipids 
against Gram-positives is different from that against Gram-negatives. 
]p1961 Activity of plant essential oils against clinical 
and environmental isolates of 
Stenotrophomonas maltophilia 
K. Kerr, A. Qureshi, M .  Drnton. t kivcrsity $,fLEcds, iii'icrohio/otqy, 
Lcrds, C K  
Objectives: To investigate the antimicrobial activity of five essential 
oils against the emerging nosocomial pathogen Stenotrophoniorius 
mulrophilia (Sni) and to determine whether, as with some conven- 
tional antimicrobials, there is temperature-dependent susceptibility to 
thew products. 
Methods: The activity of the essential oils froni hfclaleuca alterni- 
jilia, Canat~~qa odorato, Citrus beyamia, Santalurn album and P o p t e ~ n o n  
cakliii obtained by steam distillation except for Citrus berpnria (cold 
expression) war investigated. Minimal inhibitory concentrations of 
each oil for six strains of Sm were determined by a niicrodilution 
technique in modified Letheen broth at 3OoC and 37°C. 
Results: Oilc from LWaleuia a/tern@ia and Citvtts bctpniia were 
the most active (MIC O.S?h v/v). With the exception of Citvtu 
begainia, there wa\ no evidence of teiiiperature-dependent suscepti- 
bility. 
Conclusions: Sm strains are frequently resistant to most currently 
available antimicrobials, and novel therapeutic strategies should be 
sought. These preliminary data suggest that further studies with a 
wider range of essential oils employing a larger number of Sin strains 
are warranted. 
/p197j New antibiotic substances from a Ganoderma 
species 
U. Liiidequist', 11. Mothana', WD. Julich'. 'Iirsritiirc l!f Pliilrniaiy, 
P/iarniareutica/ Biology, Emst-nl~uit,--,4rndr-( h i tws i t y ,  
'Latidesk~~yicnrinstitirr Afcckleribuy- [ brpomiizcrri, (;rc!firradd, G w i a i i y  
Objectives: Many important antibiotics, e.g. penicillins, 21-e 
produced bv microscopic fungi. However, macroscopic fungi arc also 
capable of synthesizing metabolites with antiinicrobidl activity. I n  our 
screening for biologically active substancec in U~ieidiomycetes, we 
found an extract of an until now not investigated C;~~~itidrri~ia speciec 
showing strong antibacterial activity. The ohjectivc ofour  study is the 
isolation, analysis and biological investigation of the compounds 
responsible for activity. 
Methods: For the isolation and structure elucid.itioii. various 
chromatographic and spectroscopic methods were used. Microbial 
testing was done by agar diffusion test and by dilution test. 
Results: A lipophilic extract of the fruit bodies of the mushroom 
shows considerable inhibitory activity against several Gram-pocitive 
bacteria. The active substancec, which have new chemical ctructiires, 
were obtained. They are also effective against sonic multiresictant 
strains of Gram-positive bacteria. Their toxicity is very low. More 
hydrophilic extracts inhibit the growth of Grani-iieg.~tive bactem 
like Esrhui thia r d i  and Proreus mirabilis. The isolation and structure 
elucidation of the active substances from these extracts is under inves- 
tigation. 
Conclusions: The investigated extracts and compounds niay 
prove to be a prolific source of new antibiotics with 'ic-tivity against 
multiresistant bacteria. 
Ip1981 In vitro activity of Bifidobacterium bifidum 
peptides against different bacteria 
M. Svabic-Vlahovic', 11. Nikolic', L.J. Ilimitrijevic', G Ilakic', S. 
Stepanovic I. fiisiitritc qf i!firrobio/qy oiid Imnrtitidogy, St/i'riirioI t$ 
1iledicinr., I hiversiry <!f'Bc!qradr, ' h i r i m  oflniniiino/oqy o i r d  1 'fro/qqj~, 
%hk, Belgrade,, lil,'$J.i/Llt'ld 
The  objective of this ctudy was to analyze the iundaniental features 
and antibacterial activity of a refined nietdbolitr (RM) of 
B!fiduhactcriunz h$duin (BH). R M  was sep'irated from the \upernatant 
of a culture of BB grown on  a medium especially de\igned for this 
study. The obtained K M  wab further analyzed on Phasllen\ gelc, and 
the presence of two bands with molecular niassec of'approxiin'itely 6 
and 2 kDa, which indicated the peptide nature of R M ,  WJ\ estab- 
lished. Antibactcrial activity of R M  was tected by the agar diffu\ion 
method. Different Gram-positive and Gram-negative hdcteria (in 
total 70 strains) were included in the study. Some of the sti-aim were 
sensitive and the others were niultiresistant to antibiotic\. I n  order to 
determine the stability and thermostability of IXM. we tested the 
antibacterial activity of: freshly obtained R M ,  R M  stored at room 
temperature for 18 months, and R M  exposed to a temperature of 
121°C in autoclave. Holes were made in Mueller-Hinton q d r ,  and 
plates were inoculatcd with bacterial suspensions according to the 
standard antibiogram procedure. After thi5, K M  was poured into the 
holes, and after overnight incubation the diameters of zone\ of inhi- 
bition were measured. K M  showed dntibacterial activity agAirist all 
tested strains, irrespective of their senhitivity to mtibiotics. Statistical 
analysis showed no differences between the antibacterial effect9 of 
autoclaved freshly obtained and 18-month-old R M ,  or between the 
effects of non-autoclaved freshly obtained and 1 8-month-old KM.  
The obtained results indicate that R M  i\ a stable and therinost.ible 
peptide with significant antibacterial activity 
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Inhibitory effect of myristic acid analogs on 
picornaviruses 
N. Zare’, H . 2  Grunert’, 0. Raudies’, J. Katzhendler?, A. 
Honigman’, A. Panet’, M. Hodzaev’, A. Kvetnaya’, S .  Swartz*, 
H.  Zeichhardt’ , ‘Department of Virology, Institute for Infectious Diseases 
Medicine, University Hospital Benjamin Franklin, Free Urriversity o f  
Berlin, Germany; ’Faculty $Medicine, 77te Hebrew Urriversity, 
Jerusalem, Israel 
Objectives: Myristoylated proteins are important for picornavirus 
reproduction. Computer modeling of the three-dimensional struc- 
tures ofhuman rhinovirus 14 (HRV14) and poliovirus 1 (PV1) were 
the basis for the design of myristic acid (MA) analogs with modifi- 
cations along the alkyl chain. The MA analogs target the capsid 
protein VP4 to inhibit virus reproduction. 
Methods: The inhibitory effects of the MA analogs on the repro- 
duction of HRV14, PVl and coxsackievirus A21 (CoxA21) were 
tested in HeLa cells. The systems allowed differentiation ofviral repli- 
cation in the first and later reproduction cycles. Virus reproduction 
(0.1-10 m.0.i.) was analyzed for (1) virus adsorption at the host cell, 
(2) viral R N A  synthesis, (3) synthesis of new virus antigen before 
onset of the cytopathic effect (CPE), and (4) virus progeny in MA 
analog-treated and non-treated cells. Virus progeny &om treated cells 
were isolated and characterized in one-step reproduction kinetics. 
Results: The analog MI60 (500 pM) inhibited new virus antigen 
synthesis ofPVl and HRV14 at  the end ofthe first reproduction cycle 
(before CPE onset) by 83% and 90%, respectively. Virus adsorption 
at the host cell and viral RNA synthesis were hardly affected. Virus 
antigen harvested from Ml60-treated cells in later reproduction 
cycles showed strongly reduced infectivity (1.5% compared to non- 
treated virus); however, it was still capable of adsorbing to the host 
cell. 
Conclusions: The M160 analog might target picornavirus matu- 
ration, resulting in structurally altered particles which have lost their 
infectivity but could still recognize the virus receptor on permissive 
cells. 
Fiuoroquinolones I 
Ip2001 In vitro activity of moxifloxacin, a new 
methoxyquinolone, against resistant 
meningococci, Haemophilus influenzae and 
pneumococcal isolates compared to 
therapeutic and prophylactic agents 
EJ.R. Abadi, T.H. Pennington. Department of Medical Mitrobioloxy, 
Aberdeen University Medical School, Aberdeen, UK 
Neisseria meninxitidis, Haemopkilus injrrenzae and Streptococcus pneumo- 
niae are three important meningitis-causing pathogens. Resistance to 
some of the antibiotics u e d  in therapy or prophylaxis poses a serious 
problem, particularly in some countries with a high incidence of 
resistance. Therefore, an antibiotic effective against these bacteria 
would be very valuable for use in empirical therapy and prophylaxis. 
The in v i m  activity of moxifloxacin against nieningococcal 
isolates (n=30), H. injuenzae (n=6) and pneumococci (n=6) was 
determined. The isolates included sensitive as well as resistant strains 
to at least one of the standard therapeutic or prophylactic antibiotics 
used. Moxifloxacin showed very high activity against all the strains. 
MICros for moxifloxacin ranged from 0.008 to 0.05 mg/L for 
Neisseria meninxitidix, from 0.008 to 0.06 mg/L for H. ir$uenzae, and 
from 0.125 mg/L for pneumococci. 
Recent studies have also shown that the antimicrobial is safe and 
tolerable; therefore, it would be a promising agent for empirical ther- 
apy of bacterial meningitis, and clinical trials assessing its efficacy for 
the management of infections caused by these organisms are merited. 
Penetration of moxifloxacin (MFXI into sinus 
tissues following multiple oral dosing 
P. Gehanno’, H. Stass’, P. Arvis’. ’Claude Bernard Hospital, Paris, 
France; ZBnycr AG, Wuppertal, Germany; ’Bqer Pkarma, Puceaux, 
Frarite 
Objectives: To evaluate the penetration and time-course of MFX in 
sinus tissues up to 36 h, after five oral 400-mg doses. 
Methods: A total of 52 patients with chronic sinusitis undergo- 
ing surgery were enrolled in the study from February 1998 to June 
1998. Forty-eight patients (including a control group of 6 patients 
who were not to receive medication) aged 47.1 i: 13.0 years (I 9-69 
years) and weighing 72.1 2 10.8 kg (55-94 kg) were valid for safety 
analysis. A total of 39 patients, including 34 treated patients, were 
valid for PK analysis. MFX was quantified in sinus tissues and in 
plasma obtained from venous blood at corresponding times by a vali- 
dated HPLC method. 
Results: Time after dosing (T), number of patients (n), geom. 
Mean/std. dev concentrations in plasma (P) and niaxillary sinus 
mucosa (MSM), and ratios MSM/P are tabulated below: 
Similar results were observed with anterior ethmoid mucosa and 
nasal polyps. MFX was well tolerated. 
Conclusion: These results indicate that MFX readily and highly 
penetrates into sinus tissues and follows a time-course similar to its 
profile in plasma. In addition, MFX achieves concentrations several- 
fold in excess of the MICcms of all pathogens that cause acute sinusi- 
tis, such as S. pneumoniae (MICW 0.25 mg/L), for at least 36 h 
post-dose at steady state. 
[p2021 The bactericidal activity of moxifloxacin and 
other quinolones against mycobacteria 
S.H. Gillespie, D. Everett. Royal Free and University College Medical 
School, Hamnpstead, London, UK 
Objectives: To develop in vitro methods to determine bactericidal 
activity of moxifloxacin against mycobacteria. 
Methods: M.fortuitnut was used as a model system. Cultures were 
grown in Middlebrook broth and in the presence and absence of 
quinolones at varying concentrations. Viable count was performed at 
3, 6 and 16 h. Using these data it was possible to calculate the opti- 
n d  bactericidal concentration, and bactericidal index. 
Results: Moxifloxacin had a superior OBC (0.5 mg/L) than 
sparfloxacin (1.0 nig/L), ciprofloxacin (2.0 mg/L) and ofloxacin (8.0 
nig/L). 
Conclusion: Moxifloxacin has excellent bactericidal activity 
against M .  fortuitum, and similar studies in slow-growing organisms 
are now underway. 
